Re: Compiling Data on HER2 Brain Mets
Duke is starting a new Intrathecal Study using Pertuzumab and Trautuzumab for Brain mets starting in February 2016. The dosing is about what I think is going to be very therapeutic. Only enrolling limited number of patients and only for 36 weeks of treatment. It might be worth asking doctor to investigate if you have brain mets. Ask to run similar treatment under compassionate care protocol.
|